Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

By LabMedica International staff writers
Posted on 17 Nov 2026

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. More...

Blood-based biomarker assays may help researchers evaluate amyloid processing without relying on cerebrospinal fluid samples, while anti-amyloid treatment studies also require methods to assess biological responses and potential links with amyloid-related imaging abnormalities. A new plasma assay now enables quantification of multiple amyloid beta variants from a single blood sample.

C2N Diagnostics has launched C2N-Aβ-MAA (6x), a plasma multi-analyte assay for amyloid beta (Aβ) proteins. The assay uses high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) to precisely quantify six Aβ peptide variants from a single plasma sample: Aβ37, Aβ38, Aβ39, Aβ40, Aβ42, and Aβ43.

According to C2N, measuring all six variants from a single sample may improve efficiency and provide additional value in clinical research. The company expects the assay to support biopharmaceutical clinical trials investigating amyloid biology in Alzheimer’s disease and related neurodegenerative conditions. The test is available for research use only and complements C2N’s existing Aβ-MAA (6x) assay for cerebrospinal fluid.

By measuring both shorter and longer Aβ peptides, the assay is intended to help researchers evaluate how treatments affect amyloid processing. C2N said these measurements may support assessments of pharmacodynamic responses and dose selection in clinical trials, including studies of investigational therapies such as γ-secretase modulators. The assay may also support exploratory research into relationships between Aβ peptide profiles and amyloid-related imaging abnormalities associated with amyloid-targeting treatments.

C2N said its biomarkers have contributed to more than 200 clinical studies worldwide. More than 90,000 Precivity-related biomarker measurements have been reported in peer-reviewed publications, with additional manuscripts under review. The company’s clinical Precivity blood test portfolio includes PrecivityAD, PrecivityAD2, and Precivity-ApoE.

“Our introduction of the C2N-Aβ-MAA (6x) assay in blood underscores C2N’s commitment to innovation for clinical researchers by advancing novel treatment trials and providing improved diagnostic tools. This next-generation assay uses a single sample preparation to elicit important new insights into neurological conditions and treatments impacting brain amyloid processing,” said Dr. Joel Braunstein, CEO and President of C2N.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.